SkinMedica, Mass General Hospital Announce Accord

The principal investigator for this collaborative effort is David Fisher, M.D., Ph.D., chief of the Massachusetts General Hospital Department of Dermatology, director of the MGH Cutaneous Biology Research Center and Director of the Melanoma Center at MGH.He is also the Edward Wigglesworth Professor of Dermatology at Harvard Medical School and past President of the Society for Melanoma Research, the largest international society dedicated to the study of melanoma.

“We are delighted to have the opportunity to collaborate with Dr. Fisher, a world leader in dermatology research,” said Mary Fisher, CEO of SkinMedica. “His expertise in pigment and the skin’s environmental responses will be invaluable as we together pursue novel approaches for patients with a variety of pigment related concerns.”

“With this collaboration, we can progress our screening work toward understanding the role of natural products in supporting or inhibiting the processes that generate pigment, and to identifying practical solutions for these patients,” said Dr. Fisher. “Hyperpigmentation is one of the most frequently cited concerns resulting in patient visits to a dermatologist, with the most common forms being melasma, solar lentigines and post-inflammatory hyperpigmentation.”